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Results: Differences in demographic and prognostic features (age, T 
stage, Gleason score, pre-treatment PSA, ADT) were not significant. 
 
 
Figure 1 compares time-incidence curves generated using the 1st, 2nd 
and 3rd quartile D90 levels as cut-off points. A progressive, dose 
related increase in biochemical control of disease is seen with 
increasing D90. FFbR was significantly higher in patients whose D90 was 
≥ the median value compared to D90 < median (p = 0·006). Similar 
findings were seen for V100. 
 
Table 1 shows 5-year FFbR rates for D90 and V100. In multivariate 
analysis D90, (p = 0.004), V100 (p = 0.0004), PSA (p = 0.03) and ADT (p = 
0.01) were significant covariates for risk of relapse. 
Conclusions: Dichotomising the data using 6 levels of response (above 
and below Q1, Q2 and Q3) showed a clear dose response with 
progressive and continuous improvement in biochemical control of 
disease across the entire dose (and volume) range. The data show that 
a minimum D90 of 108% of the prescribed dose should be the target to 
achieve. Implant quality is an important predictor of outcome after 
HDR brachytherapy. 
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Purpose/Objective: This retrospective study was performed to 
compare different boost techniques after breast conserving therapy 
(breast conserving surgery followed by whole breast irradiation) in 
terms of local and loco-regional recurrences. 
Materials and Methods: From 2000 to 2005, 1576 patients were 
treated with breast conserving therapy for in situ or invasive breast 
cancer. An electron boost (EB) was performed for a superficial boost-
volume (less than 29 mm under the epidermis), in all other cases a 
brachytherapy boost (BTB) was proposed. When patients refused a 
BTB or a BTB was not possible because of technical reasons, a photon 
boost (PB) was given. 75.8% (1195) of the patients received an EB 
after whole breast irradiation (WBI). 16.3% (257) of the patients were 
given a BTB (either with LDR or PDR) and only 5.6% (89) of the 
patients had a PB. The primary endpoints were local and loco-regional 
recurrences. Secondary endpoints were metastasis-free survival and 
overall survival, taking into account patient and treatment 
characteristics. 
Results: The median follow-up for all patients was 8.9 years in 
invasive cancer and 8.8 years in in situ cancer. Of the 1381 invasive 
breast cancer patients, we observed 35 (2.5%) local and loco-regional 
recurrences. Five- and 10-years relapse-free survival rates were 98.8% 
and 96.9%. Five- and 10-years overall survival rates were 95.1% and 
86.2%. We found no significant differences between the three boost 
techniques with respect to relapse risk or overall survival. The 
metastasis-free survival was longer in the EB group (90.7% at 10 years) 
and the BTB group (87.3% at 10 years) than in the PB group (82.7% at 
10 years). This difference was not significant anymore after correction 
for tumor stage (pT) (p=0.09) or lymph node stage (pN) (p=0.1). Of the 
195 patients with an in situ carcinoma, we found one local and one 
loco-regional recurrence. Five- and 10-years overall survival rates in 
this group were 99.5% and 93.8%. 
Conclusions: In women treated with breast conserving therapy 
followed by a boost irradiation to the tumour bed, the local and loco-
regional recurrences at 10 years in our institution are very low for 
invasive as well as for in situ breast cancer. No difference in 
recurrence was observed comparing the three different boost 
techniques.  
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Purpose/Objective: There is currently limited evidence for HR CTV 
dose planning aims in locally advanced cervical cancer. This study 
analyses dose-response for local control in image-guided adaptive 
brachytherapy (IGABT). 
Materials and Methods: RetroEMBRACE is a retrospective study with 
796 locally advanced cervical cancer patients treated in 12 institu-
tions by IGABT using GEC ESTRO guidelines. In 592 patients data was 
available on local status, HR CTV dose and volumes. FIGO stage distri-
bution was IB (19%), IIA (7%), IIB (50%), IIIA (3%), IIIB (18%), IV (3%). 
IGABT was combined with 45-50Gy whole pelvis EBRT and weekly 
cisplatinum (76%). IGABT was based on MRI (81%) or CT (19%), and was 
administered as high dose rate (HDR) (60%) or pulsed dose rate (PDR) 
(40%). Patient groups were formed according to 1) tumour width at 
diagnosis (cut-point 50mm), 2) HR CTV volume (cut-point 35cc), 3) 
stage (IB, IIA-IIB, III-IV), 4) histology (SQ versus AC+AdSq), and 5) dose 
rate (HDR versus PDR). HR CTV D90 dose-response for local control 
was evaluated in each sub-group by logit analysis. Dose for 90% and 
95% local control (TCD90 and TCD95) was determined. 
Results: At a median follow up of 31 (3-150) months, 48 local failures 
have been observed. HR CTV volume was 35cc±24cc and HR CTV D90 
87Gy±14Gy. A significant (p<0.05) dependence of local control on D90 
for HR CTV was found in the entire patient population (Figure 1) and 
in all subgroups except PDR (p=0.07) (Table 1). Logit analysis was not 
performed in stage IB due to limited number of events: 2/32 (6%) and 
0/83 (0%) local failures above and below 80Gy, respectively. In the 
'favourable' subgroups 'width<50mm', 'HR CTV volume<35cc' and 'stage 
IIB', local control >95% was seen for HR CTV D90 larger than 87Gy, 
85Gy and 93Gy, respectively. In the 'unfavourable' subgroups 
'width>50mm', 'HR CTV volume>35cc', 'IIIA, IIIB, IVA', local control 
rates of >90% was seen for HR CTV D90 larger than 85Gy, 89Gy and 
93Gy, respectively. There was no significant difference between dose 
response for HDR and PDR (p=0.113). There was a significant differ-
ence between SQ and AC+AdSq (p=0.02) with AC+AdSq being less 
favourable, in particular for lower doses. 
 




Conclusions: Dose response for local control based on D90 of HR CTV 
is significant in a multicenter setting. Overall local control can be 
obtained in 95% of the patients when D90 of HR CTV>92 Gy. The 
analysis further points to FIGO stage, tumour width at diagnosis, 
volume of HR CTV and histology as important determinants for TCD90 
and TCD95.  
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PD-0266   
A survey of UK practice in cervical cancer radiotherapy aimed at 
developing trial specific quality assurance 
T. Simnor1, J. Conibear1, P. Diez1, E. Miles1, M. McCormack2 
1Mount Vernon Hospital, Radiotherapy Physics, Northwood Middlesex, 
United Kingdom  
2The Royal Marsden Hospital, Clinical Oncology, London, United 
Kingdom  
 
Purpose/Objective: To determine the current variation in 
radiotherapy practice for the treatment of cervical cancer across the 
United Kingdom (UK) with the aim of developing a comprehensive 
radiotherapy quality assurance (QA) programme for both external 
beam radiotherapy (EBRT) and brachytherapy within the context of 
the INTERLACE trial: a phase III trial of weekly induction 
chemotherapy and chemoradiation versus standard chemoradiation. 
The data will also be used to help determine the need for a national 
brachytherapy dosimetry audit. 
Materials and Methods: A pre-trial questionnaire was circulated to 31 
radiotherapy centres that had expressed interest in participating in 
INTERLACE. In addition to external beam radiotherapy (EBRT) details, 
in depth information on brachytherapy technique and QA was 
collected. 
Results: To date, 22 questionnaires have been completed and 
evaluated. Local practice was seen to vary significantly between 
centres with particular variation in brachytherapy techniques. For 
EBRT, all but 2 centres localise using CT and MRI modalities, only 6 of 
these also utilise PET imaging. Seven out of 22 centres use 3D virtual 
simulation (Vsim) techniques for EBRT planning. With respect to total 
EQD2 dose, 9 out of 22 centres did not achieve the proposed minimum 
dose requirement for the trial of 78 Gy, with values ranging from 68.3 
to 83.9 Gy. The intended trial requirement for the overall treatment 
time of ≤ 50 days was also not met by 7 of the 22 centres. Out of 21 
brachytherapy centres, 18 use 3D imaging for the planning of all 
fractions. Twelve of these optimise their plans for each individual 
patient; 6 to the target volume and 6 to OAR volumes or ICRU points, 
while the remaining 9 use standard plans. Six out of 21 centres have 
not participated in any brachytherapy dosimetry audit to date. 
Conclusions: The INTERLACE pre-trial questionnaire has revealed a 
wide variation in dose fractionation and treatment techniques being 
used in centres across the UK. Following our results new minimum 
standards for centres wishing to participate in the INTERLACE trial 
have been set. Now Vsim techniques for EBRT planning will not be 
permitted from UK centres. This will therefore require an advance in 
technique to 3D conformal planning for some centres. Several centres 
will be required to increase their total EQD2 dose for trial patients. 
The overall treatment time has now been amended to up to 56 days. 
Finally our results have highlighted the need for a national 
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Background: Our instituition has been treating brain metastasis using 
LINAC based stereotactic radiosurgery with micromultileaf collimator 
(Brainlab M3) since 2008. Patients are immobilised using Brainlab 
fixation and treated with static fixed fields (6MV photon). In June 
2012 a TrueBeam STX (Varian Medical Systems) was installed. Patients 
with localised CNS lesions are now treated with 10MV flattening filter 
free (FFF) volumetric modulated arc therapy VMAT.  
Purpose: This study evaluated the impact of the new technique by 
comparing beam on time (BOT), time in room (TIR), and clinical dose 
rate (CDR) with the previous technique.  
Materials and Methods: BOT (minutes:seconds) is the aggregate 
‘‘beam-on’’ time for all fields or arcs in a given plan. TIR 
(minutes:seconds) is measured from the first alignment image to last 
beam off, inclusive of all pre-treatment imaging studies and/or shifts. 
Static field patients had MV imaging only. VMAT patients had kV 
imaging and pre-treatment cone beam CT (CBCT). Clinical dose rate 
(CDR) (MU/min) is the number of monitor units (MU) divided by the 
BOT. Treatment records were reviewed for 20 patients on Varian 
Eclipse and Offline review. The median planning target volume was 
5.41cm3 (min 0.98cm3 max 18.88cm3). 18 patients had single 
metastasis, 2 patients had 2 mets.10 patients were treated with 6MV 
static fields (between 4 and 6 fields) and 10 patients with 10MV FFF 
(All 10 Patients had 2 arcs). 11 patients were treated with 20Gy, 7: 
18Gy and 2: 15Gy.  
Results 
 6X STATIC VMAT 
BOT 5:85  
Range 4:55 – 6:6 
2:60 
Range 2:01 – 3.9 
TIR 34:17  
Range 20:42-58:13 
17:12  
Range 12:42 - 28:28
MU 2726 
Range 2119-3168 
MU 6216.5  
Range 4472-9340 
CDR 600 MU/min 2385.5 MU/min 
 
Conclusions: The implementation of VMAT FFF has dramatically 
reduced the TIR. The shorter BOT reduces the likelihood of 
intrafraction motion although this cannot be verified as no post 
treatment CBCT was performed. It is envisaged that VMAT FFF 
treatment times will be reduced further as Radiographer competency 
and skill increases. This is essential in busy RT departments where 
treatment slots are at a premium.  
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Purpose/Objective: This study examined the use of Systematic 
Common Terminology Criteria for Adverse Events v. 3.0 (CTC) 
registration to enable consistent patient care and prevention of acute 
side-effects from radiotherapy (RT). The goal was to enhance the 
ability of the radiation therapist nurses (RTN) to evaluate and act on 
acute side-effects. Hence we investigated whether performing CTC 
registration on specific weekdays compared to doing the registration 
on specific treatment fractions improved the quality of patient care as 
well as the toxicity data collection. Furthermore, we studied whether 
CTC registration combined with prior delegated medical actions and 
supplementary nurse prescribing reduced the need for physician 
consultations and interventions. 
Materials and Methods: We randomly selected 20 patients treated 
with RT for rectal cancer during October 2011. At that time point, 
CTC registration was done on every fifth day of the patient's 
treatment course. We evaluated the relative number of planned CTC 
registrations actually performed and all medical interventions. This 
was compared to similar data collected for 20 randomly selected 
rectal cancer patients treated during October 2012, where CTC 
